Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study

Dornhorst, Anne; Lüddeke, Hans-Joachim; Honka, Marek; Ackermann, Ralf W.; Meriläinen, Markus; Gallwitz, Baptist; Sreenan, Séamus

doi:10.1185/030079908x260835

Cited by 30 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the German cohort of PREDICTIVE study, major hypoglycemia was significantly reduced by 55% and 51% respectively in prior NPH and glargine insulin users who switched to IDet. 19 The safety related findings of the present study are important as they have been obtained during routine clinical practice and are more realistic than those observed within the controlled environment of clinical trials. On the other hand there might also be under reporting of hypoglycemia in this study.…”

Section: Discussionmentioning

confidence: 76%

“…17,18 Interestingly, switching from glargine insulin based regimen to IDet had also led to further 0.6% reduction in HbA1c. 19 Patients with long duration of diabetes often require intensive insulin therapy for optimal glycemic control. However, intensive insulin therapy whilst improving glycemic control is associated with increased risk of hypoglycemia leading to significant morbidity and mortality.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Efficacy of Insulin Detemir Among Adult Filipino Patients with Type 2 Diabetes: The Philippine Cohort of the Global A1chieve Study

Sy¹,

Mirasol

Pasaporte³

et al. 2013

JAFES

View full text Add to dashboard Cite

Objective. To present the results from the Philippine cohort of the A1chieve study receiving insulin detemir (IDet) ± oral antidiabetic drugs.Methodology. A1chieve is a multinational, 6-month, observational study of 66,726 people with type 2 diabetes mellitus (T2DM), both insulin users and non-insulin users, started on IDet, insulin aspart or biphasic insulin aspart in 28 countries across four continents. This subgroup analysis evaluates the safety and effectiveness of IDet in 988 subjects from the Philippines.Results. At baseline the mean age, duration of diabetes and mean BMI were found to be 57±11.9 yrs, 6.9±5.3 yrs and 26±4.8 kg/m 2 respectively. Majority of subjects were insulin-naive (84.3%) and glycemic control was poor in all the groups at baseline. At the end of 24 weeks, there were significant improvements following IDet initiation with a 2.1% reduction in mean HbA1c. The HbA1c target of <7% was achieved by 46.8% subjects at the study end. Although not statistically significant, there was a modest decrease in body weight in all the groups. There was no increase in the incidence of hypoglycemia among baseline insulin-naive subjects, while a significant reduction in hypoglycemia was seen among prior insulin users.Conclusions. IDet appears to be an effective and safe option for individuals with T2DM in the Philippines. HbA1C was lowered to target, and there was no increase in incidence of hypoglycemia and body weight with IDet.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Insulin Detemir Among Adult Filipino Patients with Type 2 Diabetes: The Philippine Cohort of the Global A1chieve Study

Sy¹,

Mirasol

Pasaporte³

et al. 2013

JAFES

View full text Add to dashboard Cite

show abstract

“…Results of the PREDICTIVE study (2008) were the source of data on efficacy and safety of various basal-bolus insulin therapy regimens [8,9]. The following analyses were performed in the pharmacoeconomic study: cost-effectiveness, cost-benefit and budget impact [10][11][12].…”

Section: Methodsmentioning

confidence: 99%

“…PREDICTIVE was a multicenter, multi-national, observational study initially intended to assess the safety and efficacy of insulin detemir in patients with diabetes [8,9]. The European cohort included 20,531 patients with diabetes (7,420 with T1DM) from 11 countries.…”

mentioning

confidence: 99%

Economical advantages of insulin analogues use in basal-bolus regimen for the therapy of type 1 diabetes mellitus

Arinina¹,

Rashid²

2017

Pharmacoeconom T&P

View full text Add to dashboard Cite

PharmacoeconomicsIn the estimation of the WHO, 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. The global prevalence (age-standardized) of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.Diabetes caused 1.5 million deaths in 2012. Higher-than-optimal blood glucose level (hyperglycaemia) caused an additional 2.2 million deaths by increasing the risks of cardiovascular and other diseases. A high proportion (43%) of these 3.7 million deaths occurs before the age of 70. This parameter is higher in low-and middle-income countries than in high-income countries [1].The International Diabetes Federation (IDF) predicts that the number of people with diabetes will double by 2025, and the estimated number of people with the disease will have risen to 500 million people by 2030 [2].According to the State Register of Patients with Diabetes, 3,964,889 patients were registered in Russia as of January 1, 2014. Type II diabetes mellitus is more common, it most often occurs in people who are overweight and physically inactive. There are 339,360 people with type I diabetes mellitus, including 20,373 children, 10,038 adolescents, and 308,949 adults, and 3,625,529 patients with type II diabetes, including 409 children, 342 adolescents, and 3,624,778 adults [3].In 2016, the academician I.I. Dedov et al. published the results of their study of the economic burden of diabetes for the RF. According to their paper, the average annual treatment cost per patient with type I diabetes mellitus (T1DM) was 81.8 thousand rubles, and per patient with type II diabetes mellitus (T2DM) -70.8 thousand rubles. At that, medical costs for patients with complications of diabetes are 3 times as high as those for patients without complications, while the costs of drug therapy of the primary condition itself account for 26% only in patients with T2DM. Though the majority of T2DM patients were older than 60 years, non-medical and indirect costs accounted for almost 25% of the economic burden: in patients with T1DM, these costs accounted for 35% of the burden. The structure of medical costs depends on the diabetes type: in T1DM costs were mainly associated with the treatment of diabetes, while in T2DM half of medical costs were associated with the treatment of diabetes, and the other half -with the treatment of diabetes complications. Medication costs accounted for 69%, and hospitalization costs -for 22% of medical costs for T1DM patients. The results of regression analysis showed that the strongest predictors of medical costs growth in diabetes were the number of hospitalizations, presence of complications and insulin therapy [4].In spite of the growing demand and a high level of diabetes incidence in Russia, insulin consumption in this country is the lowest among all European countries and accounts for 39 units per citizen. As to other countries, these parameters equal 125 units in Poland, 200 -in Germany and 257 units -in Sweden, respectively [5].

show abstract

“…A recent study in patients with type 1 diabetes mellitus with severe hypoglycaemia on NPH who were changed to glargine or detemir still experienced severe hypoglycaemia and few patients reached internationally accepted glycaemic treatment goals [35]. In fact a Cochrane review article showed no glycaemic benefit of long-acting insulin analogues compared with intermediate-acting insulin [36].…”

Section: Hypoglycaemiamentioning

confidence: 99%

Insulin Analogues: Reviewing the Pros and Cons in Managing Diabetes Mellitus

Martin

Russell²,

O’Moore-Sullivan³

et al. 2011

J Pharmacogenomics Pharmacoproteomics

View full text Add to dashboard Cite

Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study

Abstract: In this open-label, prospective, observational study, insulin detemir basal-bolus therapy improved glycaemic control and reduced hypoglycaemia with weight neutrality in type 1 patients in actual clinical practice.

Cited by 30 publications

References 23 publications

Safety and Efficacy of Insulin Detemir Among Adult Filipino Patients with Type 2 Diabetes: The Philippine Cohort of the Global A1chieve Study

Safety and Efficacy of Insulin Detemir Among Adult Filipino Patients with Type 2 Diabetes: The Philippine Cohort of the Global A1chieve Study

Economical advantages of insulin analogues use in basal-bolus regimen for the therapy of type 1 diabetes mellitus

Insulin Analogues: Reviewing the Pros and Cons in Managing Diabetes Mellitus

Contact Info

Product

Resources

About